Why Is Elahere So Hard to Find? [Explained for 2026]

If you or a loved one has been prescribed Elahere (mirvetuximab soravtansine-gynx), you may already know how difficult it can be to navigate access. Unlike common prescriptions you pick up at your corner drugstore, Elahere is a specialty cancer infusion that isn't available at most pharmacies — and for good reason. Understanding why Elahere is hard to find can help you take smarter steps to access it.

What Exactly Is Elahere?

Elahere is a first-in-class antibody-drug conjugate (ADC) made by AbbVie. It received FDA accelerated approval in November 2022 and full FDA approval in March 2024 for adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior treatment regimens.

It is given as an intravenous (IV) infusion — 6 mg/kg based on adjusted ideal body weight — once every three weeks at a hospital or clinic infusion center. You cannot take Elahere at home, and it is not stocked at retail pharmacies.

Why Can't I Just Pick It Up at a Pharmacy?

There are several reasons why Elahere doesn't follow the usual pharmacy path:

It's an IV infusion, not a pill. Elahere must be administered by a healthcare professional using sterile IV equipment.

It requires a companion diagnostic test. Before your first dose, your tumor must be confirmed FRα-positive using the VENTANA FOLR1 RxDx Assay. This testing must be done at an approved lab.

It is distributed through specialty channels only. Elahere is handled through specialty pharmacies and oncology infusion centers, not general retail or mail-order pharmacies.

It requires refrigeration and special handling. Biologic ADCs like Elahere require strict cold-chain storage and preparation protocols.

Insurance prior authorization is usually required. Because Elahere costs approximately $29,307 per treatment cycle, insurance companies almost always require prior authorization before covering it — a process that can take 2-4 weeks.

Is There an Elahere Shortage?

As of 2026, Elahere is not on the FDA Drug Shortage list. However, patients can still face significant access challenges — not because of a manufacturing shortage, but because of the specialized distribution and insurance approval process. Elahere is available only through cancer centers and specialty infusion facilities, so access depends heavily on where you receive cancer care.

In the United States, not every cancer center has equal access to specialty oncology biologics. Smaller regional hospitals may have limited experience prescribing Elahere and may not have the companion diagnostic testing infrastructure in place. This creates real-world gaps between FDA approval and actual patient access.

Why Is Insurance Approval Such a Barrier?

Even when your oncologist prescribes Elahere, insurance approval isn't automatic. Here's what can slow things down:

Prior authorization documentation must confirm FRα-positive status, prior lines of therapy, and platinum-resistant disease.

Some plans require step therapy — trying and failing other chemotherapy regimens first.

Medicare patients face additional hurdles: Elahere is billed through the medical benefit (Part B), not Part D, which involves different co-pay structures.

Approval timelines vary widely — commercial insurance may take 2-4 weeks; Medicare and Medicaid may take longer.

Does Elahere Have a Patient Assistance Program?

Yes. AbbVie offers the ELAHERE Support Services (ESS) program to help patients navigate access:

Co-pay assistance: Eligible patients with commercial insurance may pay as little as $0 per treatment cycle.

Patient Assistance Program (PAP): Provides free Elahere to uninsured or underinsured patients who meet financial eligibility criteria.

Nurse Navigators: Trained nurses can answer treatment questions and provide support throughout therapy.

To enroll, ask your oncologist to submit the ELAHERE Support Services enrollment form, or call 1-833-ELAHERE (1-833-352-4373).

What If My Local Cancer Center Doesn't Offer Elahere?

If your current cancer center hasn't discussed Elahere as an option, there are steps you can take:

Ask your oncologist specifically whether your tumor has been tested for FRα expression.

Request a referral to a National Cancer Institute (NCI)-designated cancer center or a gynecologic oncologist with ADC experience.

Seek a second opinion from a gynecologic oncologist — this is not only acceptable but encouraged for complex ovarian cancer cases.

How medfinder Can Help You Locate Elahere Infusion Centers

Finding a pharmacy or infusion center that stocks and administers Elahere can be daunting. medfinder is a paid service that helps patients locate pharmacies and infusion centers near them that can fill specialty prescriptions like Elahere. By calling on your behalf, medfinder can quickly identify which facilities in your area are equipped to administer your medication — saving you hours of phone calls during an already stressful time.

Key Takeaways

Elahere is not available at retail pharmacies — it's an IV infusion administered at cancer centers.

A companion diagnostic test (VENTANA FOLR1 RxDx Assay) is required before treatment.

Access barriers relate to insurance approval, companion testing, and specialty distribution — not an FDA drug shortage.

AbbVie's ELAHERE Support Services program offers co-pay assistance and a free drug PAP for eligible patients.

For more practical guidance, read our guide on how to find Elahere in stock near you.